You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯公告精選(港股)︱上海醫藥(02607.HK)預計上半年淨利潤增長約52%

【今日焦點】

上海醫藥(02607.HK)預計上半年淨利潤增長約52%

上海醫藥(02607.HK)公告,公司預計2025年上半年度實現歸屬於母公司所有者的淨利潤爲人民幣44.50億元,與上年同期相比,將增加人民幣15.08億元,同比增長約52%。

公司於2025年4月25日完成收購上海和黃藥業有限公司10%股權的交割手續,公司合計持有上海和黃股權比例從50%變更至60%,並將其納入合併報表範圍,公司對其會計覈算由合營企業的權益法覈算變更爲按子公司覈算。根據會計準則規定,因追加投資等原因能夠對非同一控制下的被投資企業實施控制的,對於購買日之前持有的被購買方的股權,應當按照該股權在購買日的公允價值進行重新計量,公允價值與其帳面價值之間的差額計入當期投資收益。

【重大事項】

水發興業能源(00750.HK):仲裁裁決裁定前主要股東應對公司承擔3235.89萬元的彌償義務

世紀娛樂國際(00959.HK)擬成立合資從事博彩系統平臺及內容在亞太地區研發、營銷及銷售業務

立基工程控股(01690.HK)澄清稱並無拖欠其全體僱員的任何薪金或工資

德林控股(01709.HK)擬推5億港元RWA代幣化項目 含中環物業及基金權益

【財報業績】

聲通科技(02495.HK)預計上半年錄得淨溢利及經調整淨溢利不少於5000萬元

【運營數據】

中國金茂(00817.HK)6月取得簽約銷售金額156億元

德康農牧(02419.HK)6月銷售生豬82萬頭

遠洋集團(03377.HK):上半年累計協議銷售額133.7億元

中糧家佳康(01610.HK)運營快報:6月生豬出欄42.7萬頭

中樑控股(02772.HK)1至6月累計合約銷售金額約63.8億元

新城發展(01030.HK)6月實現合約銷售金額約14.93億元

江山控股(00295.HK):上半年太陽能發電站總發電量爲15.48萬兆瓦時

【醫藥創新】

復星醫藥(02196.HK):啓動蘆沃美替尼片Ⅲ期臨牀試驗 瞄準兒童低級別腦膠質瘤治療

兆科眼科-B(06622.HK):國家藥監局受理用於治療兒童近視加深的NVK002(硫酸阿託品滴眼液0.02%)的新藥上市申請

【收購出售】

華聯國際(00969.HK):附屬完成出售牙買加物業

【股權激勵】

遠東發展(00035.HK)授出合共2000萬份購股權

比亞迪電子(00285.HK)授出709.6萬股股份獎勵

心動公司(02400.HK)授出合共15.2萬份購股權

【回購註銷】

騰訊控股(00700.HK)7月9日耗資5億港元回購100.5萬股

藥明生物(02269.HK)7月9日耗資2.98億港元回購1150萬股

友邦保險(01299.HK)7月9日耗資2.74億港元回購400萬股

阿里巴巴-W(09988.HK)7月8日耗資997萬美元回購73.5萬股

美的集團(00300.HK)7月9日耗資5900萬元回購82萬股A股

匯豐控股(00005.HK)7月8日耗資9575.83萬港元回購100萬股

國泰海通(02611.HK)累計回購約6752萬股A股

渣打集團(02888.HK)7月8日耗資891.06萬英鎊回購71.8萬股

貝殼-W(02423.HK)7月8日耗資398.1萬美元回購65.9萬股

保誠(02378.HK)7月8日耗資291萬英鎊回購31.8萬股

藥明康德(02359.HK)7月9日耗資2000.7萬元回購28.57萬股A股

中國東方航空股份(00670.HK)7月9日耗資1327萬港元回購441萬股

上海電氣(02727.HK)7月9日耗資1319.8萬元回購180.3萬股A股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account